US equities |
MU $1,024.62 ▼-1.08% NVDA $229.68 ▼-0.35% SPCX $161.56 ▲+0.62% TSLA $383.28 ▲+2.21% AAPL $336.72 ▼-1.09% SNDK $1,578.81 ▼-1.90% META $719.63 ▼-0.17% AMD $607.16 ▼-2.18%
FinancialContent

Omeros Corporation - Common Stock (NQ:OMER)

19.84 +0.72 (+3.77%)
Delayed Quote Updated: 3:39 PM EDT, Oct 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Omeros Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
News headline image
Omeros (OMER) Q2 2026 Earnings Call Transcript ↗
Yartemlia generated $32.2M in gross sales during its first full quarter on market. 
Via The Motley Fool
Topics Derivatives Earnings
Let's take a look at the stocks that are in motion in today's session. ↗
Via Chartmill
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
These stocks are moving in today's pre-market session ↗
Via Chartmill
Omeros Corp (NASDAQ:OMER) Swings to Profit on YARTEMLEA Launch, Topping EPS Forecasts ↗
Via Chartmill
News headline image
Omeros Q2 Earnings Call Highlights ↗
Omeros (NASDAQ:OMER) reported second-quarter net sales of $28.5 million for YARTEMLEA, its newly launched treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy, or... 
Via MarketBeat
Topics Earnings
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Gainers ENvue Medical (NASDAQ:FEED) shares rose 49.1% to $0.61 during Wednesday's after-market session. The market value of their outstanding shares is at $2.4 million. Omeros (NASDAQ:OMER) stock moved... 
Via Benzinga
What's going on in today's after hours session ↗
Via Chartmill
News headline image
Omeros Corporation Reports Second Quarter 2026 Financial Results
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation to Announce Second Quarter Financial Results on August 12, 2026
From Omeros Corporation
Via Business Wire
News headline image
CMS Grants New Technology Add-On Payment (NTAP) Status to YARTEMLEA®
From Omeros Corporation
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMER
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
From Pomerantz LLP
Via GlobeNewswire
News headline image
Heartflow vs. Omeros: Which Healthcare Innovator Stock Is a Better Buy in 2026? ↗
Heartflow boasts rapid AI-driven growth but faces reimbursement headwinds, while Omeros bets everything on its first commercial launch. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
OMER Investors Have Opportunity to Join Omeros Corporation Fraud Investigation with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
From Pomerantz LLP
Via GlobeNewswire
News headline image
OMER Investors Have Opportunity to Join Omeros Corporation Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
Which stocks are moving on Friday? ↗
Via Chartmill
Traders are paying attention to the gapping stocks in Friday's session. ↗
Via Chartmill
Top movers in Friday's pre-market session ↗
Via Chartmill
News headline image
Omeros Corporation Announces Update on European Marketing Authorization Application for Narsoplimab in TA-TMA
From Omeros Corporation
Via Business Wire
News headline image
NovoCure vs. Omeros: Which Emerging Pharmaceutical Stock Is a Better Buy in 2026? ↗
Both companies target serious health challenges, but their financials and risk profiles reveal sharply different paths for growth-focused investors. 
Via The Motley Fool
News headline image
Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026? ↗
Intellia's CRISPR pipeline and Omeros's newly approved therapy each bring unique risk and reward profiles, see how their financials and partnerships compare. 
Via The Motley Fool
News headline image
Omeros Announces Webcast Details for Annual Meeting of Shareholders
From Omeros Corporation
Via Business Wire
News headline image
Omeros (OMER) Q4 2025 Earnings Transcript ↗
Omeros (OMER) Q4 2025 Earnings Transcript 
Via The Motley Fool
Topics Derivatives
News headline image
Omeros (OMER) Q1 2026 Earnings Transcript ↗
Omeros (OMER) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Omeros Q1 Earnings Call Highlights ↗
Omeros (NASDAQ:OMER) reported first-quarter 2026 net income of $56.1 million, or $0.78 per share, as the company began commercial sales of YARTEMLEA, its recently approved treatment for hematopoietic... 
Via MarketBeat
Topics Earnings
News headline image
Omeros Corporation Reports First Quarter 2026 Financial Results
From Omeros Corporation
Via Business Wire
News headline image
Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026
From Omeros Corporation
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >